An adequate supply of platelets is essential to repair both continuously occurring vascular damage-hemostasis-and to initiate thrombus formation following vascular injury. Whereas platelets function primarily in hemostasis, they also participate in antimicrobial host defense and secrete cytokines that can induce inflammation and growth factors that aid tissue repair. Chronic inflammation is often associated with reactive thrombocytosis (high platelet counts), such that platelets are acute phase reactants, and acute infections can result in thrombocytopenia (low platelet counts). To ensure a steady platelet supply, humans produce and remove ~1 × 10 11 platelets daily, and the rate of production can rise sharply under conditions of platelet destruction. Platelet production must be tightly regulated to avoid spontaneous bleeding if counts are low and to avoid arterial occlusion and organ damage if counts are high.
An adequate supply of platelets is essential to repair both continuously occurring vascular damage-hemostasis-and to initiate thrombus formation following vascular injury. Whereas platelets function primarily in hemostasis, they also participate in antimicrobial host defense and secrete cytokines that can induce inflammation and growth factors that aid tissue repair. Chronic inflammation is often associated with reactive thrombocytosis (high platelet counts), such that platelets are acute phase reactants, and acute infections can result in thrombocytopenia (low platelet counts). To ensure a steady platelet supply, humans produce and remove ~1 × 10 11 platelets daily, and the rate of production can rise sharply under conditions of platelet destruction. Platelet production must be tightly regulated to avoid spontaneous bleeding if counts are low and to avoid arterial occlusion and organ damage if counts are high.
TPO is the primary regulator of platelet production, supporting the survival, proliferation and differentiation of the precursors to platelets, bone marrow megakaryocytes (BMMKs) [1] [2] [3] . Hepatocytes are a major source of TPO, secreting this cytokine into the blood. However, the mechanisms regulating circulating TPO levels have been debated for decades. In one model, levels of circulating TPO are maintained solely by its uptake and metabolism by high-affinity myeloproliferative leukemia virus oncogene (Mpl) receptors on platelets and megakaryocytes [4] [5] [6] [7] [8] . In another model, circulating platelet levels regulate TPO mRNA expression in liver and BM [9] [10] [11] [12] [13] . Although no physiological ligand-receptor pair capable of regulating steady-state TPO production has yet been identified, the proinflammatory cytokine interleukin-6 (IL-6) stimulates hepatic TPO liver synthesis, providing a regulated pathway to increase platelet production during acute inflammatory responses 12, [14] [15] [16] .
Recent studies have highlighted the role of glycan modifications on platelet surface proteins in mediating platelet clearance 17, 18 . Platelets with reduced α2,3-linked sialic acid during sepsis, after cold storage or in mice lacking the sialyltransferase ST3GalIV are cleared by the hepatic endocytic AMR [19] [20] [21] [22] . The AMR is a transmembrane heteroligomeric glycoprotein complex composed of asialoglycoprotein receptor 1 (ASGPR1; also known as CLEC4H1 or HL-1) and ASGPR2 (also known as CLEC4H2 or HL-2) subunits, which are highly conserved among mammalian species 23 . However, since its discovery four decades ago, the regulatory role of the hepatic AMR has remained unclear.
We report here that the circulatory lifespan of platelets is determined by sialic acid loss that triggers platelet removal by the hepatic AMR. This removal system drives hepatic TPO mRNA expression in vivo and in vitro via JAK2 and STAT3, thereby regulating BMMKs. Disruption of desialylated platelet-AMR signaling by the JAK1/2 inhibitors AZD1480, TG101348 or BMS911543 adversely affects hepatic TPO mRNA expression and secretion. We conclude that this feedback mechanism positions the desialylated platelet-AMR pair as the critical control point for TPO homeostasis and contributes to an understanding of how JAK1/2 inhibition commonly induces thrombocytopenia in individuals with myeloproliferative neoplasms 24, 25 .
RESULTS

The AMR regulates platelet survival and thrombopoiesis in vivo
We hypothesized that circulating platelets become desialylated as they age and are removed by the hepatic AMR. We investigated platelet circulatory lifespan in mice lacking AMR function (Asgr2 −/− mice) and in St3gal4 −/− mice, in which platelets are poorly sialylated owing to genetic sialyltransferase loss and which have a marked thrombocytopenia due to rapid platelet clearance by the hepatic AMR 20, 22 . Platelet counts were elevated by 50% in Asgr2 −/− mice and platelet lifetime (t 1/2 ) was increased by ~35% compared to that of platelets in wild-type (WT) mice ( Table 1) . Platelet volume and the immature platelet fraction (IPF) (newly produced platelets) were decreased in Asgr2 −/− mice, compared to WT mice (Table 1) , consistent with the notion that platelets in Asgr2 −/− mice circulate for longer times and are older. Our results contrast with those of Grewal et al. 22 , who reported normal platelet counts in Asgr2 −/− mice. Consistent with the rapid platelet clearance, platelet volume and IPF were increased in St3gal4 −/− mice, reflecting high platelet turnover and young platelets. Platelets isolated from St3gal4 −/− mice had a significant increase in terminal galactose levels, as determined by Ricinus communis agglutinin I (RCA-I) and Erythrina cristagalli (ECL) binding ( Table 1) . Platelets isolated from Asgr2 −/− mice also had a significant increase in terminal galactose levels ( Table 1) , consistent with a prolonged platelet lifetime in the absence of the AMR removal system. BMMK counts were decreased in Asgr2 −/− mice and increased in St3gal4 −/− mice ( Table 1) . Platelet count, size, half-life and IPF were normalized in St3gal4 −/− ; Asgr2 −/− mice ( Table 1 ). Our data show that loss of AMR function allows desialylated platelets to circulate. Thus, platelets that become normally desialylated as they circulate are removed by the AMR, i.e., the number of desialylated platelets depends primarily on the AMR as a removal mechanism.
Desialylated platelet uptake by the AMR regulates hepatic TPO mRNA expression in vivo We tested whether uptake of desialylated platelets by the AMR influences steady-state hepatic TPO mRNA expression and secretion by measuring TPO mRNA expression in liver tissue isolated from Asgr2 −/− and St3gal4 −/− mice as compared to WT mice (Fig. 1a) . Hepatic TPO mRNA expression was reduced by ~45% in Asgr2 −/− Values represent mean ± s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001 using two-way ANOVA followed by Bonferroni post test. npg mice, thereby defining its minimal steady-state level. In St3gal4 −/− mice, liver TPO mRNA expression increased by 40% when compared to expression in WT liver (Fig. 1a) . The difference in TPO mRNA levels between St3gal4 −/− and Asgr2 −/− mice implies that maximal uptake of St3gal4 −/− platelets by the AMR results in a ~2.5-fold increase in liver TPO mRNA expression, compared to its minimal steady-state level. As expected, TPO mRNA levels in St3gal4 −/− ; Asgr2 −/− liver were normalized compared to WT (Fig. 1a) . Circulating plasma TPO levels, total and surface Mpl receptor expression and total platelet TPO protein levels were increased in St3gal4 −/− mice, slightly reduced in Asgr2 −/− mice and normalized in St3gal4 −/− ; Asgr2 −/− mice ( Table 1 and Supplementary Fig. 1 ). Because plasma TPO levels are regulated by internalization of Mpl upon TPO binding 6 , we investigated Mpl internalization following TPO stimulation. After incubation with 50 ng ml −1 TPO for 10 min, Mpl surface expression on control WT platelets was maximally decreased to 78 ± 3% (s.e.m.) of resting values, as evidenced by flow cytometry using an antibody directed against the extracellular domain of Mpl ( Table 1) . At the same time point after TPO treatment, Mpl expression was 96 ± 6% and 57 ± 6% in platelets isolated from Asgr2 −/− and St3gal4 −/− mice, respectively, compared to resting values of the corresponding genotypes ( Table 1) . In platelets from St3gal4 −/− ; Asgr2 −/− mice, Mpl internalization was normalized to 83 ± 3%, compared to resting values. We hypothesize that chronic thrombocytosis, as observed in Asgr2 −/− mice, in which platelets are older, is accompanied by impaired Mpl internalization, as reported for patients with essential thrombocythemia (ET) and in mouse models of thrombocytosis [26] [27] [28] . In contrast, in situations in which platelets have high turnover rates, such as in St3gal4 −/− mice, platelet Mpl expression is high and Mpl internalization is increased. Consistent with the data for plasma TPO levels, megakaryocyte numbers were significantly increased in St3gal4 −/− mice, decreased in Asgr2 −/− mice and normalized in St3gal4 −/− ; Asgr2 −/− mice ( Table 1) .
Transfusion of endogenously desialylated platelets stimulates hepatic TPO mRNA expression in vivo
To confirm that uptake of desialylated platelets by the AMR can stimulate hepatic TPO mRNA expression, we infused WT mice or Asgr2 −/− mice with endogenously desialylated platelets isolated from Asgr2 −/− (Asgr2 −/− platelets) or St3gal4 −/− (St3gal4 −/− platelets) mice. Desialylated platelets had decreased recoveries (measured at 5 min) and survival rates when transfused into WT mice (Fig. 1b) . As expected, the survival of WT, Asgr2 −/− or St3gal4 −/− platelets was prolonged in animals lacking a functional AMR (Fig. 1b) . Mouse recipients were injected with 4 × 10 8 platelets, the minimum dose required to significantly increase liver TPO mRNA expression after 12 h (Fig. 1c) . Injection of a similar number of desialylated platelets into rabbits induces de novo platelet production 29 . Notably, transfusion of St3gal4 −/− or Asgr2 −/− platelets into WT mice, but not into Asgr2 −/− mice, significantly increased hepatic TPO mRNA expression by 12 h post-transfusion (Fig. 1d) . Circulating TPO levels were initially (<24 h) decreased after injection of WT, Asgr2 −/− or St3gal4 −/− platelets into WT mice (Fig. 1e) , consistent with previous reports 6 . Thereafter, plasma TPO concentrations in mice injected with desialylated, but not WT, platelets significantly increased in parallel with TPO mRNA levels, peaking by day 2 post-infusion. TPO mRNA expression and TPO plasma concentrations did not increase above preinjection levels at time points >24 h after transfusion of WT or desialylated platelets into Asgr2 −/− mice (Fig. 1d,e) . Consistent with the increases in liver TPO mRNA expression and TPO plasma concentrations, transfusion of St3gal4 −/− or Asgr2 −/− platelets into WT mice, but not into Asgr2 −/− mice, increased BMMK numbers at day 3 post-injection, and platelet counts peaked at day 10 ( Fig. 1f-h) . A peak in platelet numbers at day 10 after desialylated platelet treatment is consistent with observations in rabbits 29 . Transfusion of desialylated platelets into Mpl −/− mice had no effect on platelet counts ( Supplementary  Fig. 2) , indicating that the increase in platelet count is dependent on TPO and its receptor Mpl. MK and platelet numbers were unaffected , using GAPDH as a loading control (n = 3 independent experiments). *P < 0.05, **P < 0.01 using one-way ANOVA followed by Bonferroni post test, all groups compared to WT mice that were untreated (b,d) or treated with vehicle (c). (Fig. 1f-h ). Of note, splenectomy in WT or Asgr2 −/− mice had no long-term effects on platelet count, platelet surface terminal β-galactose exposure or TPO plasma levels (Supplementary Fig. 3 ).
Uptake of desialylated platelets stimulates hepatic JAK2-STAT3 signaling in vivo
If platelet uptake by the AMR is able to induce TPO mRNA transcription, the appropriate signaling pathways must become active in hepatocytes. Hence, we investigated signals activated by the uptake of desialylated platelets by AMR. Major polypeptides of 60-70 and 125 kDa were highly tyrosine-phosphorylated in WT liver lysates (Fig. 2a) . Using a specific antibody directed against JAK2, we identified the 125-kDa polypeptide as the tyrosine kinase JAK2. The presence of additional phosphoproteins of 125 kDa cannot be excluded. Analysis of liver samples revealed a marked reduction in the phosphorylation of JAK2 in Asgr2 −/− mice and a significant increase in St3gal4 −/− mice (Fig. 2a,b) . We next investigated STAT proteins, downstream effectors of JAK2 signaling. STAT3 phosphorylation was significantly higher in liver samples from St3gal4 −/− mice compared to the other liver samples tested (Fig. 2a,b) . Tyrosine phosphorylation of STAT1, STAT5A, STAT5B and STAT6 was not detected (data not shown). Liver from Asgr2 −/− mice showed a marked reduction in the level of phosphorylated STAT3 compared to control liver (Fig. 2a,b ). To directly demonstrate that platelet binding of the AMR induces an increase in TPO mRNA expression through JAK2 activation, we administrated the clinically used JAK1/2 inhibitor AZD1480 or the JAK2 inhibitor TG101348 to WT mice for 2 d. Liver samples of mice treated with AZD1480 showed a significant decrease in total tyrosine phosphorylation (pTyr), and liver samples of mice treated with either of the JAK inhibitors showed decreased tyrosine phosphorylation of JAK2 and STAT3 (Fig. 2a,b and Supplementary Fig. 4 ). Treatment with AZD1480 or TG101348 also blocked TPO mRNA expression in WT mice 12 h after infusion of desialylated platelets from St3gal4 −/− or Asgr2 −/− mice (Fig. 2c) . We observed a slight but reproducible decrease in TPO mRNA expression in the liver of WT mice treated with AZD1480 or TG101348 (Fig. 2c) . Consistent with the TPO mRNA liver data, TPO protein expression was increased in St3gal4 −/− and decreased in Asgr2 −/− mice compared to WT levels (Fig. 2d) . AZD1480 or TG101348 treatment also decreased TPO protein expression in WT mice (Fig. 2d and Supplementary Fig. 4) . 19, 20 and produce TPO in response to IL-6 (ref. 14). We tested whether ingestion of desialylated human platelets by the AMR affects TPO mRNA expression and secretion by HepG2 cells. Human platelets were desialylated using α2-3,6,8 neuraminidase (sialidase), as confirmed by RCA-I binding (Fig. 3) . By 6 h after incubation of desialylated platelets with HepG2 cells, the rate of platelet uptake by HepG2 cells was markedly accelerated ( Fig. 3a) and TPO mRNA (threefold) and protein (1.8-fold) expression were increased (Fig. 3b,c) . TPO protein secretion into the culture medium was also increased (Fig. 3d) . In contrast, TPO mRNA expression was only slightly increased after 0.5-2 h of incubation with sialidase-untreated platelets (1.6-fold) and returned to below baseline levels within 6 h (Fig. 3b) . We next investigated tyrosine phosphorylation of JAK2 and its downstream effector, STAT3, in HepG2 cells. Incubation of HepG2 cells with desialylated platelets induced a strong, transient JAK2 tyrosine phosphorylation response at 0.5 h, whereas the addition of control platelets induced a prolonged but weaker JAK2 tyrosine phosphorylation response (Fig. 3f) . We observed STAT3 tyrosine phosphorylation and nuclear translocation 1 h after addition of either control or desialylated human platelets (Fig. 3e,g ). As judged by immunofluorescence at 6 h, TPO protein expression in the cells was increased by the addition of desialylated platelets (Fig. 3h) , and the TPO was packaged into granular structures, indicative of secretory granules (Fig. 3h) . To determine the role of the AMR in TPO expression, we transfected HepG2 cells with siRNA targeting ASGR2, which led to downregulation of ASGR2 expression to ~80% of its normal values (Supplementary Fig. 5 ). ASGR2 siRNA transfection inhibited STAT3 translocation to the nucleus (Fig. 3g) and blocked the increases in TPO mRNA (Fig. 3j) and TPO protein ( Fig. 3h and Supplementary Fig. 5) .
To investigate the effects of JAK2 inhibition on TPO protein expression, we pretreated HepG2 cells for 24 h with AZD1480, TG101348 or BMS911543 before addition of desialylated platelets. Treatment with the JAK1/2 inhibitors inhibited JAK2 phosphorylation ( Supplementary  Fig. 6 ) and translocation of STAT3 to the nucleus ( Fig. 3i and  Supplementary Fig. 6 ) and prevented the increases in TPO mRNA (Fig. 3j) and protein ( Fig. 3i and Supplementary Fig. 6 ) expression. Together, the data show that the hepatic AMR signals via JAK2-STAT3 to stimulate TPO mRNA expression in vivo and in vitro.
Exogenously desialylated platelets stimulate hepatic TPO mRNA expression As an alternative approach, we desialylated WT platelets in vitro using sialidase and transfused them into WT and Asgr2 −/− mice. Depletion of sialic acid was documented by RCA-I lectin binding (Fig. 4) . As expected, desialylated platelets were rapidly removed from the circulation of WT mice, with only ~15% remaining after 1 h (Fig. 4a) . In contrast, ~90% of the untreated platelets remained in the circulation at the same time point (Fig. 4a) . Removal was highly dependent on a functional liver AMR, because desialylated platelets circulated for a longer period of time in Asgr2 −/− mice (Fig. 4a) . Hepatic TPO mRNA expression increased by ~50% in WT mice 12 h after injection with desialylated platelets, plasma TPO levels increased at day 2, platelet numbers increased at day 3 and BMMK numbers increased at day 4 ( Fig. 4c-f) . TPO mRNA expression was unaffected in WT mice injected with control platelets or in Asgr2 −/− mice injected with desialylated platelets (Fig. 4b) . Similarly, direct injection of sialidase induced a severe (>95%) thrombocytopenia in WT mice after 24 h, which was incomplete (~60%) in Asgr2 −/− mice (Fig. 4g) . Moreover, sialidase injection induced an AMR-dependent increase in liver TPO mRNA expression, plasma TPO levels and BMMK numbers in WT but not Asgr2 −/− mice (Fig. 4h-j) .
Antibody-mediated thrombocytopenia does not stimulate liver TPO mRNA expression The role of Mpl in regulating of TPO plasma levels is evident in animal models with induced acute immune thrombocytopenia (IT), in which liver TPO mRNA expression remains unchanged but Data are mean ± s.e.m. of 6 WT and 4 Asgr2 −/− recipients otherwise specified. *P < 0.05. Two-way ANOVA followed by Bonferroni post test, all groups compared to WT mice transfused with untreated platelets. (g-j) Blood platelet counts (g), liver TPO mRNA expression (h), plasma TPO levels (i) and BMMK numbers (j) in WT and Asgr2 −/− mice injected or not with sialidase. BMMK numbers were measured 3 d after injection. Data are mean ± s.e.m. of five mice per group.*P < 0.05, **P < 0.01, ***P < 0.001. One-way ANOVA followed by Bonferroni post test, all groups compared to treated with -sia platelets (a-i) or to control WT mice (basal).
circulating TPO levels are elevated 4 . Based on these studies, we tested whether hepatic TPO mRNA expression in Asgr2 −/− and St3gal4 −/− mice is regulated independently of platelet sialic acid loss in a model of acute IT. Injection of rabbit anti-mouse platelet serum (RAMPS) induced a severe (>99%) thrombocytopenia in WT, Asgr2 −/− and St3gal4 −/− mice within 24 h, and platelets did not return to the circulation of these animals until 72 h post-RAMPS treatment (Fig. 5a) . Moreover, RAMPS-induced thrombocytopenia did not stimulate liver TPO mRNA expression in WT, Asgr2 −/− and St3gal4 −/− mice (Fig. 5b) . Plasma TPO levels increased markedly within 24 h (Fig. 5c ) and BMMK numbers increased at 72 h after RAMPS treatment, independently of the genotype (Fig. 5d) . Thus, platelets cleared independently of the AMR fail to increase hepatic TPO mRNA expression.
DISCUSSION
Our study shows that the AMR recognizes circulating desialylated platelets under steady-state conditions and functions as a direct feedback pathway between desialylated senile platelet removal and hepatic TPO mRNA expression and secretion via JAK2-STAT3 signaling (Supplementary Fig. 7 ). This previously unrecognized feedback mechanism for TPO production adds new insights into previous observations that thrombocytopenia is a common and clinically significant adverse event associated with JAK1/2 inhibition 24, 25 . Platelets lose sialic acid as they age in the circulation, presumably as a result of their exposure to sialidases. This loss defines their lifespan, as evidenced by microthrombocytosis in Asgr2 −/− mice despite increased levels of platelet surface terminal β-galactose, which would normally lead to their recognition by the AMR. Platelet survival also depends on the interplay between prosurvival and proapoptotic members of the Bcl-2 family, key regulators of the intrinsic apoptotic pathway [30] [31] [32] . Whether members of the Bcl-2 family alter platelet surface sialic acid content is unclear. Notably, the primary site of platelet clearance following administration of the proapoptotic drug ABT-737 is the liver 33 , whereas the spleen does not regulate senescent platelet life span 31 . Consistent with this notion, our study showed no significant difference in platelet counts between WT and Asgr2 −/− mice following splenectomy.
Our data showed that hepatic TPO mRNA expression and secretion are stimulated by the AMR-mediated uptake of either endogenously or exogenously desialylated platelets, both in vivo and in vitro. Human and mouse platelets do not contain TPO mRNA 34 , indicating that TPO mRNA expression is intrinsic to hepatocytes in vivo following engagement of desialylated platelets with the AMR, consistent with our data showing AMR regulation of TPO mRNA expression by HepG2 cells in vitro. Supporting this model, St3gal4 −/− mice had high liver TPO mRNA expression as a result of increased platelet clearance by the AMR. In contrast, Asgr2 −/− mice had low liver TPO mRNA expression, as they were genetically unable to clear desialylated platelets through this receptor, thereby defining the minimal steady state for TPO production.
The mechanisms regulating steady-state TPO production have been the subject of discussion for decades. In one model, hepatic TPO production is constitutive, and TPO serum levels are maintained solely by TPO uptake and metabolism by platelets and megakaryocytes [4] [5] [6] [7] [8] . This prevailing model posits that the circulating TPO concentration is inversely proportional to the 'Mpl mass' contributed by the total number of MKs and platelets. A reciprocal relationship between platelet number and circulating TPO level is clearly evident in patients after bone marrow transplant 3 and in Mpl −/− mice 35, 36 . Furthermore, serum TPO levels increase, whereas hepatic TPO mRNA levels remain unchanged, in models of acute immune or chemotherapy-induced thrombocytopenia [4] [5] [6] [7] [8] . In another model of TPO regulation, platelet counts are sensed by an unidentified mechanism, resulting in appropriately regulated levels of TPO expression in the liver and the BM [9] [10] [11] 13 . This hypothesis is based on observations that liver TPO mRNA expression is not constitutive, as it can be stimulated by IL-6 during reactive inflammatory thrombocytosis or epithelial ovarian cancer 12, 15, 16 or after selective liver irradiation 37 . However, the physiological signal and receptor necessary to stimulate hepatic TPO production has until now remained elusive. Our study identifies desialylated platelets and the AMR as the physiological ligand-receptor pair regulating steady-state hepatic TPO mRNA production in vivo. In this platelet aging and injury sensing system, liver TPO mRNA expression is uncoupled from total platelet counts and instead senses desialylated platelets as they age in blood or under conditions of increased desialylation such as sepsis 21, 22 . Platelets cleared independently of the AMR, such as by antibody-mediated removal of platelets, fail to increase hepatic TPO mRNA expression, consistent with previous studies [5] [6] [7] [8] .
Several observations in humans and mice lend credence to the assertion that platelet TPO metabolism is not the sole determinant of plasma TPO levels. Serum TPO levels are lower than expected in patients with IT [38] [39] [40] and are higher than expected in patients with ET [40] [41] [42] . Serum TPO levels are normal in mice lacking the transcription factor NF-E2, which is essential for erythroid and megakaryocytic maturation and differentiation, despite thrombocytopenia 43 , and mice deficient for Bak and Bax have normal to slightly increased serum TPO levels despite significantly increased platelet counts 31 . Circulating TPO concentrations are therefore likely to be regulated in a complex manner, a notion further supported by data showing that Mpl expression on megakaryocytes and platelets is not required for thrombopoiesis but is essential to prevent myeloproliferation 36 . Student's t test (d). Two-way ANOVA followed by Bonferroni post test, all groups compared to WT mice. Data are mean ± s.e.m. of five mice per genotype. *P < 0.05, **P < 0.01, ***P < 0.001.
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Asialo-platelet-AMR induction of hepatic TPO mRNA expression could explain why TPO synthesis is increased in ET but decreased in IT. ET would lead to an increase in the number of desialylated platelets, a condition that increases TPO expression. In contrast, platelet clearance by immune mechanisms involving macrophage Fcγ receptors would lead to high levels of young, sialylated platelets in the circulation, shunting platelets away from the AMR and reducing TPO expression. Thus, our data provide a partial explanation for the discrepancies in plasma TPO levels observed in human pathologies with defects in platelet counts and in liver disease. Regulation of liver TPO mRNA expression by the AMR does not exclude the possibility that total platelet counts and Mpl expression levels participate in regulating plasma TPO levels as a fine-tuning regulatory mechanism. Indeed, the effects we observed on Mpl expression, plasma TPO levels and BMMK numbers in Asgr2 −/− and St3gal4 −/− mice suggest that changes in TPO mRNA expression in the liver do not fully explain platelet turnover kinetics.
Our data demonstrate that the AMR, in addition to its known role as an endocytic receptor 23 , regulates gene expression. The AMR signaling cascade involves JAK2 phosphorylation and STAT3 phosphorylation and translocation to the nucleus. The characterized AMR signaling cascade shares similarities with that of IL-6 (ref. 44) , in which binding of IL-6 to its hepatic receptor (IL-6R) engages the signal transducing subunit gp130, leading to STAT3 tyrosine phosphorylation and activation by gp130-associated JAK1. Whether JAK2 and STAT3 directly associate with the AMR is unknown. A tyrosine kinase of 127 kDa, possibly JAK2, constitutively associates with the AMR ASGPR1 subunit in HepG2 cells 45 . Notably, IL-6 stimulates TPO mRNA expression in hepatocytes in vivo and in HepG2 and Hep3B cells in vitro 12, [14] [15] [16] . Thus, our study suggests that desialylated platelets and IL-6 both lead to STAT3-mediated hepatic TPO mRNA expression, downstream of the AMR-JAK2 and IL-6R-JAK1 signaling cascades, respectively.
The clinically used JAK1/2 inhibitor AZD1480 and the JAK2 inhibitors TG101348 and BMS911543 blocked STAT3 activation and TPO mRNA production downstream of AMR binding, both in mice and in cultured human HepG2 cells, confirming that JAK1/2-STAT3 signals to TPO production in vitro and in vivo. Thrombocytopenia is a common adverse event of JAK1/2 inhibitors, which are clinically used in treating patients with myeloproliferative neoplasms, whether or not their disease is associated with the somatic JAK2 mutation V617F (refs. 24,25) . JAK1/2 inhibitors target both mutant JAK2-V617F in hematopoietic stem and precursor cells and wild type JAK2, activation of which is essential for red blood cell and platelet production 46, 47 . Our study indicates that inhibition of TPO production downstream of hepatic AMR-JAK2 signaling (and likely downstream of hepatic IL-6R-JAK1 signaling) could additionally contribute to the thrombocytopenia associated with JAK1/2 treatment.
In conclusion, the AMR-mediated removal of desialylated senile platelets regulates TPO synthesis in the liver by recruiting JAK2 and STAT3. Our study identifies desialylated senile platelets and the AMR as the long-elusive physiological ligand-receptor pair regulating hepatic TPO mRNA production, helping to resolve the longstanding mystery of steady-state TPO regulation.
METHODS
Methods and any associated references are available in the online version of the paper. to immunoblot analysis using anti-human ASGR2 antibody (cat. no. N-17, dilution 1:1,000, Santa Cruz Biotechnology). To determine the effects of ASGR2 silencing on TPO expression, HepG2 cells were transfected with scramble or ASGR2 siRNA at 30 µM final concentration; 36 h after transfection, human platelets treated or not with sialidase were added to the cells, and harvest occurred at the indicated time points.
Immunoblotting. Livers were isolated from WT, Asgr2 −/− and St3gal4 −/− mice and from WT mice treated with AZD1480 or TG101348 and lysed. HepG2 cells were harvested after 0, 0.5, 1 and 2 h incubation with sialidase-treated or control human platelets and lysed in 3× NP40 buffer. Liver and HepG2 lysates were subjected to SDS-PAGE and immunoblotting using anti-phosphotyrosine 4G10 (dilution 1:4,000, Millipore, USA), anti-pJAK2 (cat. no. 3776S, dilution 1:1,000), anti-JAK2 (cat. no. 3230, dilution 1:2,000), anti-pSTAT3 (cat. no. 9145, dilution 1:1,000), anti-STAT3 (cat. no. 9132, dilution 1:1,000) (Cell Signaling Technology) and anti-TPO [mouse (cat. no. AF-488-NA, dilution 1:1,000), and human (cat. no. AF-288-NA, dilution 1:1,000) both from R&D systems]. Band intensities from four individual western blots were quantified by densitometric analysis using software ImageJ.
Bone marrow histology. Mouse femurs were fixed in 4% paraformaldehyde/PBS for 48 h and decalcified in 0.5 M EDTA (Boston BioProducts), pH 7.8, for 5 d, exchanging EDTA twice. Tissues were paraffin-embedded, and sections were stained with hematoxylin and eosin 52 . Megakaryocytes were counted by 3 different individuals in 20 randomly selected fields for each condition. All cohorts contained at least 6 mice.
Splenectomy. Platelet count was determined by flow cytometry before surgical splenectomy. Mice were anesthesized using 2-3% isoflurane. The left upper abdominal cavity was entered and exposed via median incision. After the spleen was identified, the organ was gently manipulated through the incision and covered with a moist saline gauze. Splenic arteries and venous supply were dissected and knots placed with 10-0 nylon suture, followed by spleen removal. The incision was closed with 5-0 prolene suture. Mice were monitored for 48 h and received buprenorphine analgesic for 72 h. After a recovery period of 14 d, platelet counts and surface β-galactose were measured by flow cytometry as described above. Plasma TPO levels were determined as described above.
Data analyses. Numerical data were analyzed using one-way (for single variant) or two-way (for multiple variants) analysis of variance followed by Bonferroni adjustment for multiple comparisons. Two groups were compared by the twotailed Student's unpaired t test. The significance of data was assessed using the GraphPad Prism 5 software. Differences were considered as significant when P < 0.05. Different levels of significance are indicated as *P < 0.05, **P < 0.01, ***P < 0.001. No statistical method was used to predetermine sample size.
